Telix Pharmaceuticals Ltd (TLX)

Sydney


Symbol		Exchange		Currency
TLX	·	Sydney	·	AUD	Delayed
TLX	·	NASDAQ	·	USD	Real-time

Currency in AUD

TLX Pro Research

15.000

+0.200(+1.35%)

Closed·02:04:59

Fair Value

Unlock Value

Day's Range

14.850

15.315

52 wk Range

8.260

29.640

TLX Income Statement

Explore the detailed Telix Pharmaceuticals Ltd income statement, offering a comprehensive view of the company’s financial performance. Review essential metrics such as revenue, gross profit, operating income, and net income over selected periods. This page provides a clear breakdown of profitability and operational efficiency, helping you evaluate Telix Pharmaceuticals Ltd's growth trends and overall financial health.

Period Ending:

2016

31/12

2017

31/12

2018

31/12

2019

31/12

2020

31/12

2021

31/12

2022

31/12

2024

01/01

2024

31/12

2025

31/12

Total Revenues

aa.aa

5.51

109.07

332.98

516.55

803.79

Total Revenues Growth

aa.aa

+37.49%

+1,877.87%

+205.28%

+55.13%

+55.61%

Cost Of Revenues

aa.aa

1.85

44.4

129.7

197.06

421.95

Gross Profit

aa.aa

3.66

64.67

203.28

319.49

381.85

Gross Profit Growth

aa.aa

+49.37%

+1,664.69%

+214.32%

+57.17%

+19.52%

Gross Profit Margin %

aa.aa

66.46%

59.29%

61.05%

61.85%

47.51%

Other Operating Expenses, Total

aa.aa

62.65

115.16

168.3

263.61

362.56

	Other Operating Expenses, Total Growth
	R&D Expenses
	Selling General & Admin Expenses
	Other Operating Expenses

aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	+55.27%	+83.82%	+46.15%	+56.63%	+37.54%
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	24.78	55.19	85.32	127.93	171.25
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	34.11	59.34	83.13	135.52	192.56
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-	0.63	-0.14	0.16	-1.25

Operating Income

aa.aa

-58.99

-50.49

34.98

55.88

19.29

Operating Income Growth

aa.aa

-55.65%

+14.41%

+169.28%

+59.76%

-65.49%

EBIT Margin %

aa.aa

-1,069.6%

-46.29%

10.5%

10.82%

2.4%

Net Interest Expenses

aa.aa

-0.12

-0.22

0.15

2.39

-7.94

Net Interest Expenses Growth

aa.aa

-24.04%

-85.38%

+168.83%

+1,480.13%

-432.65%

Interest Expense, Total

aa.aa

-0.12

-0.22

-0.52

-4.79

-13.76

Interest And Investment Income

aa.aa

0.67

7.18

5.83

Other Non Operating Expenses, Total

aa.aa

11.47

-5.1

-9.3

-7.75

-27.67

EBT, Excl. Unusual Items

aa.aa

-47.63

-55.81

25.83

50.52

-16.32

Gain (Loss) On Sale Of Assets

aa.aa

Other Unusual Items, Total

aa.aa

-10.78

-11.38

-23.24

-6.85

11.05

EBT, Incl. Unusual Items

aa.aa

-58.42

-67.19

2.59

37.92

-5.27

EBT, Incl. Unusual Items Growth

aa.aa

-58.39%

-15.02%

+103.86%

+1,361.64%

-113.89%

EBT, Incl. Unusual Items Margin

aa.aa

-1,059.31%

-61.6%

0.78%

7.34%

-0.66%

Income Tax Expense

aa.aa

0.03

3.72

-1.61

4.23

1.86

Net Income to Company

aa.aa

-58.45

-70.91

4.21

33.69

-7.13

Minority Interest

aa.aa

Net Income

aa.aa

-58.45

-70.91

4.21

33.69

-7.13

Net Income Growth

aa.aa

-69.24%

-21.32%

+105.93%

+700.5%

-121.15%

Net Income Margin %

aa.aa

-1,059.9%

-65.01%

1.26%

6.52%

-0.89%

Preferred Dividend and Other Adjustments

aa.aa

Net Income to Common Excl. Extra Items

aa.aa

-58.45

-70.91

4.21

33.69

-7.13

Basic EPS - Continuing Operations

aa.aa

-0.21

-0.23

0.01

0.1

-0.02

Basic EPS - Continuing Operations Growth

aa.aa

-54.29%

-10.21%

+105.78%

+671.43%

-120.74%

Diluted EPS - Continuing Operations

aa.aa

-0.21

-0.23

0.01

0.1

-0.02

Diluted EPS - Continuing Operations Growth

aa.aa

-53.83%

-10.21%

+105.7%

+650.77%

-121.62%

Basic Weighted Average Shares Outstanding

aa.aa

204.88

211.64

319.18

331.23

337.88

Diluted Weighted Average Shares Outstanding

aa.aa

204.88

211.64

323.71

345.19

337.88

Dividend Per Share

aa.aa

Dividend Per Share Growth

aa.aa

EBITDA

aa.aa

-55.71

-47.41

38.17

59.64

32.46

EBITDA Growth

aa.aa

-61.1%

+14.89%

+180.5%

+56.26%

-45.57%

EBITDA Margin %

aa.aa

-1,010.12%

-43.47%

11.46%

11.54%

4.04%

EBIT

aa.aa

-58.99

-50.49

34.98

55.88

19.29

* In Millions of USD (except for per share items)

FAQ

What was Telix Pharma’s revenue at year end?

At the end of the last reported fiscal year, Telix Pharma (TLX) recorded total revenue of 803.794 million USD.

How much revenue did Telix Pharma report in the most recent quarter?

In its most recent quarterly earnings report, Telix Pharma posted revenue of 413.435 million USD.

What was Telix Pharma’s net income for the year?

For the full year, Telix Pharma reported net income of -7.125 million USD.

How much net income did Telix Pharma post in the last quarter?

In the most recent quarter, Telix Pharma (TLX) posted net income of -4.833 million USD.

What was Telix Pharma’s gross profit for the year?

Gross profit for the year was reported at 381.845 million USD.

How much gross profit did Telix Pharma generate last quarter?

Telix Pharma recorded gross profit of 192.071 million USD in its latest quarterly report.

What was Telix Pharma’s annual operating income?

For the full year, Telix Pharma (TLX) reported operating income of 19.287 million USD.

What was Telix Pharma’s operating income last quarter?

Quarterly operating income was 8.037 million USD.

What was Telix Pharma’s quarterly EBITDA?

In the latest quarter, EBITDA was reported at 14.189 million USD.

What was the quarter-over-quarter change in EBITDA for Telix Pharma?

EBITDA changed by -22.341% million USD compared to the last quarter.

How did Telix Pharma’s revenue change compared to the previous quarter?

Revenue changed by 5.911% million USD compared to the prior quarter.

What was the quarter-over-quarter change in gross profit for Telix Pharma?

In the latest quarter, gross profit changed by 1.210% million USD from the previous quarter.

US 30

48,544.70

+81.0

+0.17%

US 500

7,036.50

+13.6

+0.19%

Dow Jones

48,463.72

-72.27

-0.15%

S&P 500

7,022.95

+55.57

+0.80%

Nasdaq

24,016.02

+376.93

+1.59%

S&P 500 VIX

18.17

-0.19

-1.03%

Dollar Index

97.807

-0.044

-0.04%

Investing Challenges

Join our investing challenges and compete for rewards while you learn!

Market Movers

Name	Last	Chg. %	Vol.
NVDA	198.87	+1.20%	185.34M
TSLA	391.95	+7.62%	113.81M
AAPL	266.43	+2.94%	49.91M
MSFT	411.22	+4.61%	45.06M
MU	456.23	-2.03%	40.37M
AVGO	396.72	+4.19%	29.56M
SNDK	891.72	-5.58%	16.27M

Trending Stocks

Name	Last	Chg. %	Vol.
TSLA	391.95	+7.62%	113.81M
NVDA	198.87	+1.20%	185.34M
MSFT	411.22	+4.61%	45.06M
MU	456.23	-2.03%	40.37M
ORCL	169.81	+4.18%	43.01M

Most Undervalued Stocks

Name	Last	Upside	Fair Value
Aaaaaa Aaaaaaa	61.29	+68.26%	103.13
Aa Aaaaaaaaaa	244.66	+64.07%	401.41
Aaaa Aaa Aa	268.63	+59.04%	427.23
Aaaaaaaaaaa	194.00	+54.46%	299.65
Aaaaaa Aa Aa	28.30	+52.89%	43.27
A Aaaaaa Aa	389.72	+50.20%	585.36
Aaaaa A Aa	17.60	+45.59%	25.62

Name	Last	Upside	Fair Value
Aaaaaa Aaaaaaa	61.29	+68.26%	103.13
Aa Aaaaaaaaaa	244.66	+64.07%	401.41
Aaaa Aaa Aa	268.63	+59.04%	427.23
Aaaaaaaaaaa	194.00	+54.46%	299.65
Aaaaaa Aa Aa	28.30	+52.89%	43.27
A Aaaaaa Aa	389.72	+50.20%	585.36
Aaaaa A Aa	17.60	+45.59%	25.62

See full list

Install Our AppScan QR code to install app

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

Name	Last	Chg. %	Vol.
TEAM	66.00	+10.53%	10.88M
DASH	179.94	+10.02%	7.00M
DDOG	121.06	+9.49%	5.48M
SHOP	127.41	+8.30%	9.31M
TSLA	391.95	+7.62%	113.81M
NOW	94.19	+7.29%	25.84M
APP	464.63	+7.18%	4.92M

Name	Last	Chg. %	Vol.
CARR	58.55	-9.45%	16.95M
SWK	67.18	-6.94%	3.88M
LYV	155.82	-6.29%	6.43M
IR	83.39	-5.58%	5.98M
AOS	63.37	-5.32%	2.41M
NEM	113.04	-5.25%	9.26M
INSM	146.74	-4.34%	2.23M

Popular Searches

Please try another search

Telix Pharmaceuticals Ltd (TLX)

TLX Income Statement

FAQ

What was Telix Pharma’s revenue at year end?

How much revenue did Telix Pharma report in the most recent quarter?

What was Telix Pharma’s net income for the year?

How much net income did Telix Pharma post in the last quarter?

What was Telix Pharma’s gross profit for the year?

How much gross profit did Telix Pharma generate last quarter?

What was Telix Pharma’s annual operating income?

What was Telix Pharma’s operating income last quarter?

What was Telix Pharma’s quarterly EBITDA?

What was the quarter-over-quarter change in EBITDA for Telix Pharma?

How did Telix Pharma’s revenue change compared to the previous quarter?

What was the quarter-over-quarter change in gross profit for Telix Pharma?

Trending Stocks